The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018
{{output}}
Background: The difference between the costs of the newer and older glucose-lowering drugs (GLMs) has been steadily increasing since 2010. In 2018, newer drugs cost 8-12 times more than older drugs (except for insulin). This stud... ...
